Reason for request



Clinical Benefit


Substantial actual benefit

Clinical Added Value

no clinical added value

EYLEA 40 mg/ml, solution for injection in a prefilled syringe and solution for injection in a vial, does not provide an improvement in actual benefit (IAB V) compared with LUCENTIS 10 mg/ml, solution for injection.

Contact Us

Évaluation des médicaments

See also

All our publications